Data used in ITI model
| ITI regimen | Dose FVIII 100 U/kg/d |
| Duration 420 d | |
| Annual number bleeding episodes | Minor |
| Low = 3 | |
| Average = 15 | |
| High = 27 | |
| Moderate = 3 | |
| Major = 0.2 | |
| Weight of cohort members | |
| At entry (5 y old) | 20 kg |
| By 20 y old | 70 kg |
| Excess risk annual hazard rate for mortality | |
| With inhibitor | 4× |
| Without inhibitor | 2.5× |
| Factor concentrate cost | Cost (1997 Redbook AWP-10%) |
| FVIII (recombinant) | $1.11 |
| aPCC | $1.17 |
| pFVIII | $1.56 |
| Anti-pFVIII inhibitor titer | 25% antihuman titer |
| ITI regimen | Dose FVIII 100 U/kg/d |
| Duration 420 d | |
| Annual number bleeding episodes | Minor |
| Low = 3 | |
| Average = 15 | |
| High = 27 | |
| Moderate = 3 | |
| Major = 0.2 | |
| Weight of cohort members | |
| At entry (5 y old) | 20 kg |
| By 20 y old | 70 kg |
| Excess risk annual hazard rate for mortality | |
| With inhibitor | 4× |
| Without inhibitor | 2.5× |
| Factor concentrate cost | Cost (1997 Redbook AWP-10%) |
| FVIII (recombinant) | $1.11 |
| aPCC | $1.17 |
| pFVIII | $1.56 |
| Anti-pFVIII inhibitor titer | 25% antihuman titer |